Samik Pharmaceutical Company LTD. (KOSDAQ:014950)
South Korea flag South Korea · Delayed Price · Currency is KRW
9,760.00
-1,000.00 (-9.29%)
At close: Apr 2, 2026

KOSDAQ:014950 Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023
Period Ending
Dec '25 Dec '24 Dec '23
Operating Revenue
60,02055,85751,229
Other Revenue
-0-0-
60,02055,85751,229
Revenue Growth (YoY)
7.45%9.04%-
Cost of Revenue
17,72217,11917,359
Gross Profit
42,29838,73833,870
Selling, General & Admin
36,56232,61228,847
Research & Development
2,0601,9431,757
Amortization of Goodwill & Intangibles
5.082556.12
Other Operating Expenses
279.95302.34287.89
Operating Expenses
39,02535,06031,073
Operating Income
3,2733,6782,796
Interest Expense
-29.22-12.26-18.53
Interest & Investment Income
301.52186.69198.16
Currency Exchange Gain (Loss)
0.921.751.36
Other Non Operating Income (Expenses)
-3,893213.21147.23
EBT Excluding Unusual Items
-346.444,0673,124
Gain (Loss) on Sale of Investments
348.99300.14298.32
Gain (Loss) on Sale of Assets
45.989.50.07
Asset Writedown
--23.8-
Pretax Income
48.524,3533,423
Income Tax Expense
803.41830.99453.53
Net Income
-754.893,5222,969
Net Income to Common
-754.893,5222,969
Net Income Growth
-18.62%-
Shares Outstanding (Basic)
877
Shares Outstanding (Diluted)
877
Shares Change (YoY)
8.46%0.15%-
EPS (Basic)
-99.00501.00423.00
EPS (Diluted)
-99.00501.00423.00
EPS Growth
-18.44%-
Free Cash Flow
-1,3463,543874.05
Free Cash Flow Per Share
-176.56503.91124.52
Gross Margin
70.47%69.35%66.11%
Operating Margin
5.45%6.59%5.46%
Profit Margin
-1.26%6.31%5.80%
Free Cash Flow Margin
-2.24%6.34%1.71%
EBITDA
4,6495,0294,074
EBITDA Margin
7.75%9.00%7.95%
D&A For EBITDA
1,3761,3511,278
EBIT
3,2733,6782,796
EBIT Margin
5.45%6.59%5.46%
Effective Tax Rate
1655.90%19.09%13.25%
Advertising Expenses
669.39565.36753.43
Source: S&P Global Market Intelligence. Standard template. Financial Sources.